CD274 and neoplasm: Given that over 70% of tumors escape immune surveillance via the PD-1/PD-L1 pathway, targeting PD-L1 can ensure the immune monitoring of PD-L1-high-expressing tumor cells, triggering their destruction upon dysregulation (52).